Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
Seeking Alpha / 5 hours ago 3 Views
Seeking Alpha / 5 hours ago 3 Views
Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance
Comments